Keryx Biopharmaceuticals

Part of Akebia Therapeutics

CompanyUnited States

Keryx Biopharmaceuticals develops 2 assets, the furthest approved (ferric citrate in hyperphosphatemia in dialysis-dependent chronic kidney disease). Mostly small molecule and other; based in the United States.

2
Assets
Furthest stage
Approved
13
Trials
11
Signals

Pipeline

2
  • ferric citrate

    Binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels.

    Approved, Small molecule, hyperphosphatemia in dialysis-dependent chronic kidney disease, iron deficiency anemia in non-dialysis-dependent chronic kidney disease

  • sulodexide

    Glycosaminoglycan mixture that enhances antithrombin and heparin cofactor II activity and supports endothelial glycocalyx integrity.

    Phase 3, no development reported, Other, diabetic kidney disease, peripheral arterial obstructive disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms3
  • Trials18
  • Deals1
  • Signals13
  • Similar companies6

Intelligence